This filing announces that AstraZeneca has submitted a US New Drug Application (NDA) for ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) for MET-driven EGFR-mutated non-small cell lung cancer (NSCLC). This submission is significant as it seeks approval for a new, all-oral treatment option supported by positive Phase III trial data, potentially expanding treatment options and market share for the involved companies.
HUTCHMED announced that AstraZeneca has submitted a US New Drug Application (NDA) for ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) for MET-driven EGFR-mutated non-small cell lung cancer (NSCLC). This is a significant development as it represents a potential new, all-oral treatment option for a specific patient population that has progressed on EGFR-TKI therapy. The application is supported by positive data from the SAFFRON Phase III trial, which demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival. This news is positive for both HUTCHMED, as the co-developer of ORPATHYS, and AstraZeneca, as the lead developer and marketer of the combination. Short-term, this could lead to increased investor confidence and potential stock price appreciation for both companies. Long-term, successful approval and commercialization would open up a new revenue stream and strengthen their positions in the oncology market. Traders should watch for further updates on the FDA review process and potential approval timelines.